CADL - NASDAQ

Candel Therapeutics, Inc.

CADL·NASDAQ

$8.80

+4.5%

HealthcareBiotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$483.13M

EPS-0.7200

P/E Ratio-12.22

Earnings Date08/13/2026

cadl

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Candel Therapeutics, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

CADL · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Candel Therapeutics, Inc. NASDAQ:CADL	0.00	N/A	N/A	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	97.00K	189.4%	N/A	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	81.00K	N/A	N/A	N/A
Galectin Therapeutics Inc. NASDAQ:GALT	0.00	N/A	N/A	N/A
Aldeyra Therapeutics, Inc. NASDAQ:ALDX	0.00	N/A	N/A	N/A
Cabaletta Bio, Inc. NASDAQ:CABA	25.00K	-13.8%	N/A	N/A
Editas Medicine, Inc. NASDAQ:EDIT	0.00	N/A	N/A	N/A
Capricor Therapeutics, Inc. NASDAQ:CAPR	283.15K	6.3%	N/A	55.1%
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	260.00K	34.0%	N/A	N/A
Genelux Corporation NASDAQ:GNLX	9.00K	-13.7%	35.1%	N/A

Candel Therapeutics, Inc. Fair Value Envelope

CADL · NASDAQ

Our analysis suggests that CADL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.8, this represents a potential HIDDEN relative to our calculated worth for Candel Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.8

Related Guides

Blog Categories

Continue your CADL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.